PharmaResources (Shanghai) Co. Ltd. A Market Cap ($811.00 Million)
Market Cap & Net Worth: PharmaResources (Shanghai) Co. Ltd. A (301230)
PharmaResources (Shanghai) Co. Ltd. A market cap. PharmaResources (Shanghai) Co. Ltd. A (SHE:301230) has a market capitalization of $811.00 Million (CN¥5.54 Billion) as of November 6, 2026. Listed on the SHE stock exchange, this China-based company holds position #9545 globally and #2376 in its home market, demonstrating a 9.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaResources (Shanghai) Co. Ltd. A's stock price CN¥30.63 by its total outstanding shares 180941126 (180.94 Million). Also see 301230 operating cash flow for how efficiently the company converts equity into cash flow.
PharmaResources (Shanghai) Co. Ltd. A Market Cap History (2022–2026)
PharmaResources (Shanghai) Co. Ltd. A market cap history from 2022 to 2026. Data shows growth from $754.57 Million to $811.00 Million (2.88% CAGR). Check 301230 stock price for real-time trading data and today's change.
PharmaResources (Shanghai) Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaResources (Shanghai) Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is PharmaResources (Shanghai) Co. Ltd. A growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.15x
PharmaResources (Shanghai) Co. Ltd. A's market cap is 1.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
23.06x
PharmaResources (Shanghai) Co. Ltd. A's market cap is 23.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $754.57 Million | $478.88 Million | $67.18 Million | 1.58x | 11.23x |
| 2023 | $716.33 Million | $489.72 Million | $37.62 Million | 1.46x | 19.04x |
| 2024 | $675.70 Million | $544.47 Million | $17.08 Million | 1.24x | 39.55x |
| 2025 | $790.88 Million | $688.35 Million | $34.29 Million | 1.15x | 23.06x |
Competitor Companies of 301230 by Market Capitalization
Companies near PharmaResources (Shanghai) Co. Ltd. A in the global market cap rankings as of November 6, 2026. Also see 301230 total assets for a full breakdown of the balance sheet.
Key companies related to PharmaResources (Shanghai) Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of PharmaResources (Shanghai) Co. Ltd. A (2022–2026)
Market capitalization of PharmaResources (Shanghai) Co. Ltd. A from 2022 to today. Between 2022 and today, PharmaResources (Shanghai) Co. Ltd. A's market cap moved from $754.57 Million to $ 811.00 Million, with a yearly change of 2.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥811.00 Million | +2.54% |
| 2025 | CN¥790.88 Million | +17.05% |
| 2024 | CN¥675.70 Million | -5.67% |
| 2023 | CN¥716.33 Million | -5.07% |
| 2022 | CN¥754.57 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of PharmaResources (Shanghai) Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $811.00 Million USD |
| MoneyControl | $811.00 Million USD |
| MarketWatch | $811.00 Million USD |
| marketcap.company | $811.00 Million USD |
| Reuters | $811.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturin… Read more